The Journal of Clinical and Aesthetic Dermatology

Matrix Medical Communications
  • 5.0 (3)
  • MEDICINE

JCAD's audio platform provides interviews with leading experts in the dermatology field. 

  1. Eight-Week Outcomes With Deuruxolitinib in Alopecia Areata

    16H AGO

    Eight-Week Outcomes With Deuruxolitinib in Alopecia Areata

    Send a text Amy McMichael, MD, a clinical professor and chair of the Department of Dermatology at Wake Forest School of Medicine, discusses deuruxolitinib for patients with alopecia areata. She highlights its 8-week efficacy compared to placebo in clinical trials. The medication provided significant improvement in hair regrowth at the 8-mg dose, with minimal adverse events. She emphasized the need to perform standard baseline and intermittent lab tests in patients, similar to other Janus kinase inhibitors.

    6 min
  2. The Use of Gene-Expression Profile Testing for Effective Atopic Dermatitis Treatment

    16H AGO

    The Use of Gene-Expression Profile Testing for Effective Atopic Dermatitis Treatment

    Send a text James Del Rosso, DO, and David Cotter, MD, PhD, discuss using gene expression profile testing, such as the AdvanceAD-Tx test, to provide effective treatment for patients with atopic dermatitis. AdvanceAD-Tx allows clinicians to match therapy based on patients’ immune profiles using molecular testing. Drs. Del Rosso and Cotter also review the benefits of using the test not only at baseline, but also throughout treatment in order to tailor their atopic dermatitis therapy and avoid constantly cycling through treatments.

    19 min
  3. Understanding Long-Term Treatment Success in a Patient With Psoriasis

    2D AGO

    Understanding Long-Term Treatment Success in a Patient With Psoriasis

    Send a text Graham Litchman, DO, MS, a board-certified dermatologist at Vivida Dermatology in Las Vegas, Nevada, discusses a patient case involving a 54-year-old female patient with psoriasis who did not respond well to conventional treatments or systemic steroids. Dr. Lichtman introduced her to risankizumab (Skyrizi), explaining its mechanism of action, adverse events, and dosing schedule. The patient experienced significant improvement by the 3-month mark, with most plaques disappearing. After 1 year of treatment, the patient had only a small area of plaques.

    9 min
  4. James Del Rosso, DO: JCAD January 2026 Issue Highlights

    JAN 30

    James Del Rosso, DO: JCAD January 2026 Issue Highlights

    Send us a text James Del Rosso, DO, the Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the January 2026 issue of JCAD.

    23 min
  5. Aaron Farberg, MD: Real-World Experiences in Alopecia Areata Treatment

    JAN 22

    Aaron Farberg, MD: Real-World Experiences in Alopecia Areata Treatment

    Send us a text Dr. Aaron Farberg, a board-certified dermatologist and founder of Bear Dermatology in Dallas, Texas, discusses the evolving treatment landscape for alopecia areata with a focus on Janus kinase inhibitors and how he has used this type of treatment in his practice.

    5 min
  6. Arash Mostaghimi, MD, MPH, FAAD: Considerations for the Use of Deuruxolitinib in Patients with Alopecia Areata

    12/02/2025

    Arash Mostaghimi, MD, MPH, FAAD: Considerations for the Use of Deuruxolitinib in Patients with Alopecia Areata

    Send us a text Dr. Mostaghimi discusses the speed and depth of efficacy of deuruxolitinib for providing hair regrowth in patients with severe alopecia areata.

    5 min
  7. James Del Rosso, DO: JCAD November 2025 Issue Highlights

    11/20/2025

    James Del Rosso, DO: JCAD November 2025 Issue Highlights

    Send us a text Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the November 2025 issue of JCAD.

    20 min
  8. Extended-cut Podcast—James Del Rosso, DO, and David G. Cotter, MD, PhD: Targeting the IL-31 Neuroimmune Pathway for Treating Prurigo Nodularis

    11/13/2025

    Extended-cut Podcast—James Del Rosso, DO, and David G. Cotter, MD, PhD: Targeting the IL-31 Neuroimmune Pathway for Treating Prurigo Nodularis

    Send us a text Drs. Del Rosso and Cotter discuss advances in the molecular understanding of prurigo nodularis, which have enabled the development of targeted pharmaceuticals that treat the root of this condition.

    22 min
See All (51)

Ratings & Reviews

5
out of 5
3 Ratings

About

JCAD's audio platform provides interviews with leading experts in the dermatology field. 

Information